Incannex Healthcare vs Serina Therapeutics
IXHL and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IXHL and SER compare
Serina Therapeutics is the larger company, worth 1.5 times as much as Incannex Healthcare ($36.3M against $24.8M).
Incannex Healthcare scores higher on the StockData Score (7 against 2 for Serina Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IXHL | SER |
|---|---|---|
| Size and price | ||
| Market cap | $24.8M | $36.3M |
| Share price | $1.98 | $1.43 |
| Change, 1 year | −81.8% | −63.4% |
| Change, 5 years | – | 81.0% |
| Beta (5Y) | 1.96 | −1.09 |
| Employees | 12 | 16 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× | – |
| FCF yield | −52.0% (better) | −58.4% |
| Growth | ||
| Revenue growth, 5Y average | – | −18.5% |
| Profitability | ||
| Return on equity | −47.8% (better) | −1175% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 48.81 (better) | 6.65 |
| Altman Z-score | −0.61 | −0.10 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −280% | – |
| Shareholder yield | −280% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 3.6% | 5.5% |
| Held by insiders | – | 49.7% |
| Insider net buying, 12 months | – | −$232K |
| Short interest, % of float | – | 0.37% |
Go deeper
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
- SER stock overview
- SER income statement
- SER valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.